Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.
OBJECTIVE
Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer.


METHODS
Forty patients with < or =5 metastatic lesions received curative-intent SBRT, while 11 patients with >5 lesions, undergoing SBRT to < or =5 metastatic lesions, were treated with palliative-intent.


RESULTS
Among those treated with curative-intent, 4-year actuarial outcomes were: overall survival of 59%, progression-free survival of 38% and lesion local control of 89%. On univariate analyses, 1 metastatic lesion (versus 2-5), smaller tumor volume, bone-only disease, and stable or regressing lesions prior to SBRT were associated with more favorable outcome. Patients treated with palliative-intent SBRT were spared morbidity and mortality from progression of treated lesions, though all developed further metastatic progression shortly (median 4 months) after enrollment.


CONCLUSIONS
SBRT may yield prolonged survival and perhaps cure in select patients with limited metastases. Palliative-intent SBRT may be warranted for symptomatic or potentially symptomatic metastases.
Milano
Michael T
MT
Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, P.O. Box 647, Rochester, NY 14642, USA. MTMilano@yahoo.com
Zhang
Hong
H
Metcalfe
Su K
SK
Muhs
Ann G
AG
Okunieff
Paul
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D010865:Pilot Projects; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D015996:Survival Rate; D016896:Treatment Outcome